With richer countries pumping billions of dollars into funding experimental COVID-19 vaccines, pricing and supply of potential treatments have been widely debated.
A report this week claims AstraZeneca could start profiting from its vaccine as soon as next July.
The Financial Times reported on Wednesday (Oct 7), that the British drugmaker can declare when it considers the pandemic to have ended.
AstraZeneca previously said it would not profit from the vaccine "during the pandemic".
The London-listed firm has developed the vaccine with Oxford University.
It's signed multiple supply-and-manufacture deals for more than 3 billion doses globally, although details on the terms have been scant.
According to FT, the "Pandemic Period" could be further extended beyond July 2021, but only if AstraZeneca "acting in good faith considers that the pandemic is not over."
The company said it has created multiple supply chains to ensure that access to its vaccine is timely and affordable for high- and low-income countries alike.
It's also been granted protection from future liability claims.
In a statement on Thursday (October 8), AstraZeneca said it would seek expert guidance, including from global organisations, as to when it can say that the pandemic is behind us.